{"filing":{"accession_number":"0002007919-26-000044","cik":"0002007919","ticker":"INBX","company_name":"Inhibrx Biosciences, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"inhibrx-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/inhibrx-20260813.htm"},"events":[{"id":27634,"run_id":25198,"accession_number":"0002007919-26-000044","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Inhibrx issued a press release on August 13, 2026 announcing financial results for the three and six months ended June 30, 2026, including revenue, operating expenses, net loss, cash position, and balance sheet data. This is a standard quarterly earnings disclosure furnished under Item 2.02, with the press release attached as Exhibit 99.1. The disclosure is material as it reports significant financial metrics including a net loss of $36.7 million for Q2 2026 and changes in the company's cash and debt position.","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29225,"accession_number":"0002007919-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibrx issued a press release on August 13, 2026 announcing financial results for the three and six months ended June 30, 2026, including revenue, operating expenses, net loss, cash position, and balance sheet data. This is a standard quarterly earnings disclosure furnished under Item 2.02, with the press release attached as Exhibit 99.1. The disclosure is material as it reports significant financial metrics including a net loss of $36.7 million for Q2 2026 and changes in the company's cash and debt position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:05:02.412269+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29225,"accession_number":"0002007919-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibrx issued a press release on August 13, 2026 announcing financial results for the three and six months ended June 30, 2026, including revenue, operating expenses, net loss, cash position, and balance sheet data. This is a standard quarterly earnings disclosure furnished under Item 2.02, with the press release attached as Exhibit 99.1. The disclosure is material as it reports significant financial metrics including a net loss of $36.7 million for Q2 2026 and changes in the company's cash and debt position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:05:02.412269+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-08-13"}]}